Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
22 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug...
Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
09 août 2019 16h15 HE
|
Abeona Therapeutics Inc.
Five patients with MPS IIIB treated in the Transpher B Study of ABO-101 gene therapy Positive interim MPS IIIA data showed preservation of neurocognitive development in youngest patients with robust...
Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
06 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...
Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA
25 juil. 2019 09h15 HE
|
Abeona Therapeutics Inc.
Neurocognitive development of youngest patients preserved 12-18 months post treatment; development scores remain within range of unaffected children Robust and sustained biomarker improvement across...
Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
17 juil. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
04 avr. 2019 08h25 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 04, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy development, today announced that the U.S. Food...
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
18 mars 2019 16h45 HE
|
Abeona Therapeutics Inc.
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 ...
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
11 févr. 2019 16h05 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for...
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
08 janv. 2019 13h00 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
06 déc. 2018 12h30 HE
|
Abeona Therapeutics Inc.
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS IIIA) Novel AIMTM AAV...